Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1235P is a **pseudogene** of the U6 small nuclear RNA gene family. U6 snRNA is a highly conserved, abundant non-coding RNA that functions as a core component of the spliceosome, catalyzing pre-mRNA splicing in the nucleus of eukaryotes[1][3]. However, RNU6-1235P is not a functional gene but a non-coding genomic sequence derived from U6 snRNA through retrotransposition or duplication events, typically mediated by LINE-1 elements[4][5]. Most U6 snRNA pseudogenes do not produce functional RNAs and have no known cellular role—they are considered "processed pseudogenes" and serve primarily as **genomic fossils/markers of retrotranspositional dynamics** inside the genome[4][5]. There are hundreds of U6 snRNA pseudogenes in the human genome, and they are **not considered drug targets, receptors, or enzymes**. They are not associated with known disease mechanisms or phenotypes and have no known therapeutic, diagnostic, or prognostic use[4][5]. Further clarification: The core gene, U6 snRNA, is a functional RNA essential for the spliceosome[1][3]. Many pseudogene copies of U6 exist across the genome, including RNU6-1235P, but these are not biologically active and are not targeted by drugs[4][5]. There is nothing inherently "incorrect" in the gene symbol or nomenclature, but the entity is **not a functional therapeutic target**—thus, it should be flagged as "not a target" for pharmacological or clinical interest[4][5]. If a therapeutic or biomarker relationship for a pseudogene is being proposed, that would be inconsistent with current biological understanding for the RNU6 pseudogene family. Summary: **RNU6-1235P is a pseudogene derived from the core spliceosomal U6 snRNA gene; it is not a receptor, not druggable, not associated with disease, and does not encode a functional product**[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1235, pseudogene (RNU6-1235P).